Last year, Insulet Corp generated 1.92B USD for its biggest-performing segment, U.S.Omnipod. The United States made the largest contribution, accounting for 1.95B USD last year. For the latest quarter, Insulet Corp reported the revenue of 544.10M USD for the period ending 2026-06-30, which came from the top-performing segment, U.S.Omnipod. United States contributed the highest revenue, at 549.90M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

U.S.Omnipod

International Omnipod

Drug Delivery

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

U.S.Omnipod

1.92B(70.89%)

1.51B(72.86%)

1.25B(73.71%)

884.80M(67.79%)

651.50M(59.29%)

526.90M(58.26%)

420.40M(56.95%)

323.53M(57.38%)

271.60M(58.56%)

301.67M(82.20%)

International Omnipod

754.30M(27.85%)

523.40M(25.27%)

410.10M(24.16%)

363.00M(27.81%)

359.90M(32.75%)

308.00M(34.06%)

253.10M(34.29%)

172.02M(30.51%)

119.95M(25.86%)

--(--)

Drug Delivery

34.10M(1.26%)

38.90M(1.88%)

36.00M(2.12%)

57.50M(4.41%)

87.40M(7.95%)

69.50M(7.68%)

64.70M(8.76%)

68.28M(12.11%)

72.22M(15.57%)

65.31M(17.80%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

All Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

United States

1.95B(72.15%)

1.55B(74.73%)

1.29B(75.84%)

942.30M(72.19%)

738.90M(67.25%)

596.40M(65.94%)

485.10M(65.71%)

391.80M(69.49%)

343.81M(74.14%)

295.10M(80.41%)